Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis

doi:10.1084/jem.171.1.63

This Article

	Full Text (PDF, 754K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Shahin, R. D.
	Articles by Manclark, C. R.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Shahin, R. D.
	Articles by Manclark, C. R.


Social Bookmarking

	What's this?

ARTICLES

Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis

RD Shahin, MJ Brennan, ZM Li, BD Meade and CR Manclark
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892.

Immunization with the 69-kD outer membrane protein (OMP) of Bordetella pertussis protected neonatal mice against lethal respiratory challenge with B. pertussis 18323. Active immunization elicited a serum IgG anti- 69-kD OMP response at the time of challenge, with IgG anti-69-kD OMP antibodies detected in bronchoalveolar lavage fluid after challenge. Intravenous administration of BPE8, a monoclonal IgG1 anti-69-kD OMP, also protected young mice against B. pertussis challenge. Intravenously injected BPE8 was detected in the lungs of mice at the time of aerosol challenge, suggesting that the presence of specific antibody in the lungs may mediate protection. Thus the 69-kD OMP of B. pertussis is a protective antigen in mice that elicits specific serum antibody that can transude to the lung. The 69-kD OMP was detected in a preparation of a Takeda acellular vaccine by immunoblot analysis and a serum antibody response to the 69-kD OMP was observed in 18-mo-old children boosted with this preparation of Japanese acellular vaccine. Our results demonstrate that the B. pertussis 69-kD OMP is a protective antigen in animals, is immunogenic in humans, and is present in a preparation of acellular pertussis vaccine that is widely used in Japan. These findings indicate that the 69-kD OMP should be seriously considered as a candidate for inclusion in new formulations of antigenically defined acellular pertussis vaccines.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Elahi, S., Buchanan, R. M., Babiuk, L. A., Gerdts, V. (2006). Maternal Immunity Provides Protection against Pertussis in Newborn Piglets.. Infect. Immun. 74: 2619-2627 [Abstract] [Full Text]
Elahi, S., Brownlie, R., Korzeniowski, J., Buchanan, R., O'Connor, B., Peppler, M. S., Halperin, S. A., Lee, S. F., Babiuk, L. A., Gerdts, V. (2005). Infection of Newborn Piglets with Bordetella pertussis: a New Model for Pertussis. Infect. Immun. 73: 3636-3645 [Abstract] [Full Text]
Bruss, J. B., Siber, G. R. (2002). Quantitative Priming with Inactivated Pertussis Toxoid Vaccine in the Aerosol Challenge Model. Infect. Immun. 70: 4600-4608 [Abstract] [Full Text]
King, A. J., Berbers, G., van Oirschot, H. F. L. M., Hoogerhout, P., Knipping, K., Mooi, F. R. (2001). Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147: 2885-2895 [Abstract] [Full Text]
Boursaux-Eude, C., Guiso, N. (2000). Polymorphism of Repeated Regions of Pertactin in Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica. Infect. Immun. 68: 4815-4817 [Abstract] [Full Text]
Leef, M., Elkins, K. L., Barbic, J., Shahin, R. D. (2000). Protective Immunity to Bordetella pertussis Requires Both B Cells and Cd4+ T Cells for Key Functions Other than Specific Antibody Production. JEM 191: 1841-1852 [Abstract] [Full Text]
Mills, K. H.�G., Ryan, M., Ryan, E., Mahon, B. P. (1998). A Murine Model in Which Protection Correlates with Pertussis Vaccine Efficacy in Children Reveals Complementary Roles for Humoral and Cell-Mediated Immunity in Protection against Bordetella pertussis. Infect. Immun. 66: 594-602 [Abstract] [Full Text]
Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A. E., Anemona, A., Ciofi degli Atti, M. L., Giammanco, A., Panei, P., Blackwelder, W. C., Klein, D. L., Wassilak, S. G.F., The Progetto Pertosse Working Group, (1996). A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis. NEJM 334: 341-349 [Abstract] [Full Text]
Gustafsson, L., Hallander, H. O., Olin, P., Reizenstein, E., Storsaeter, J. (1996). A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine. NEJM 334: 349-356 [Abstract] [Full Text]
Halperin, S. A., Barreto, L., Friesen, B., Meekison, W. (1994). Immunogenicity of a Five-Component Acellular Pertussis Vaccine in Infants and Young Children. Arch Pediatr Adolesc Med 148: 495-502 [Abstract]
Annunziato, P. W., Rothstein, E. P., Bernstein, H. H., Blatter, M. M., Reisinger, K. S., Pichichero, M. E. (1994). Comparison of a Three-Component Acellular Pertussis Vaccine With a Whole-Cell Pertussis Vaccine in 4- Through 6-Year-Old Children. Arch Pediatr Adolesc Med 148: 503-507 [Abstract]
Kimura, M., Kuno-Sakai, H., Sato, Y., Kamiya, H., Nii, R., Isomura, S., Horiuchi, K., Kato, T., Deguchi, M., Saikusa, H., Mortimer, E. A. Jr, Cherry, J. D. (1991). A Comparative Trial of the Reactogenicity and Immunogenicity of Takeda Acellular Pertussis Vaccine Combined With Tetanus and Diphtheria Toxoids: Outcome in 3- to 8-Month-Old Infants, 9- to 23-Month-Old Infants and Children, and 24- to 30-Month-Old Children. Arch Pediatr Adolesc Med 145: 729-733 [Abstract]